Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas

Blood

Volumn 122, Issue 5, 2013, Pages 705-714

  Massa, Paul E ^a   Paniccia, Aida ^a   Monegal, Ana ^a,b   De Marco, Ario ^b,c   Rescigno, Maria ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF NOVA GORICA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD20 ANTIBODY; GANCICLOVIR; NANOBODY; RECOMBINANT ANTIBODY; THYMIDINE KINASE; TUMOR ANTIGEN; CD20 ANTIGEN; MONOCLONAL ANTIBODY; PRODRUG; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIOPHAGE; CANCER IMMUNOTHERAPY; CELL INVASION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; MOUSE; NONHUMAN; PLASMID; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; XENOGRAFT; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; LYMPHOMA; METABOLISM; METHODOLOGY; NONOBESE DIABETIC MOUSE; PATHOLOGY; REMISSION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HUMANS; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; PRODRUGS; RECOMBINANT PROTEINS; REMISSION INDUCTION; SALMONELLA TYPHIMURIUM; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883740916     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-474098     Document Type: Article

References (34)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-998.
2. Forbes NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer. 2010;10(11):785-794.
3. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142-152.
4. Avogadri F, Martinoli C, Petrovska L, et al. Cancer immunotherapy based on killing of Salmonellainfected tumor cells. Cancer Res. 2005;65(9):3920-3927.
5. Avogadri F, Mittal D, Saccheri F, et al. Intratumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immunol. 2008;38(7):1937-1947.
6. Vendrell A, Gravisaco MJ, Pasetti MF, et al. A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. Vaccine. 2011;29(4):728-736.
7. Manuel ER, Blache CA, Paquette R, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res. 2011;71(12):4183-4191.
8. Saccheri F, Pozzi C, Avogadri F, et al. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med. 2010;2(44):44ra57.
9. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148(6):1081-1084.
10. Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol. 2007;1(1):42-54.
11. Bagshawe KD. Targeting: the ADEPT story so far. Curr Drug Targets. 2009;10(2):152-157.
12. Monegal A, Ami D, Martinelli C, et al. Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. Protein Eng Des Sel. 2009;22(4):273-280.
13. Cultrera JL, Dalia SM. Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Contr. 2012;19(3):204-213.
14. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981;291(5812):238-239.
15. Li J, Peet GW, Balzarano D, et al. Novel NEMO/ IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem. 2001;276(21):18579-18590.
16. Dull T, Zufferey R, Kelly M, et al. A thirdgeneration lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471.
17. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109(11):4708-4715.
18. Ben-Jacob E, Coffey DS, Levine H. Bacterial survival strategies suggest rethinking cancer cooperativity. Trends Microbiol. 2012;20(9):403-410.
19. Martinoli C, Chiavelli A, Rescigno M. Entry route of Salmonella typhimurium directs the type of induced immune response. Immunity. 2007;27(6):975-984.
20. Ohno K, Yoshizawa H, Tsukada H, et al. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells. J Immunol. 1996;156(10):3875-3881.
21. Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 2006;66(4):2442-2450.
22. Scibelli A, Matteoli G, Roperto S, et al. Flavoridin inhibits Yersinia enterocolitica uptake into fibronectin-adherent HeLa cells. FEMS Microbiol Lett. 2005;247(1):51-57.
23. Shah SA, Halloran PM, Ferris CA, et al. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 1993;53(6):1360-1367.
24. Kanazawa T, Mizukami H, Okada T, et al. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther. 2003;10(1):51-58.
25. Leschner S, Deyneko IV, Lienenklaus S, et al. Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory logic. Nucleic Acids Res. 2012;40(7):2984-2994.
26. Dunlap NE, Benjamin WH Jr, McCall RD Jr, Tilden AB, Briles DE. A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in mice. Microb Pathog. 1991;10(4):297-310.
27. Stocker BA. Aromatic-dependent salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them. J Biotechnol. 2000;83(1-2):45-50.
28. Arrach N, Cheng P, Zhao M, Santiviago CA, Hoffman RM, McClelland M. High-throughput screening for salmonella avirulent mutants that retain targeting of solid tumors. Cancer Res. 2010;70(6):2165-2170.
29. MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell. 2007;11(5):431-445.
30. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. Efficient tumor targeting by singledomain antibody fragments of camels. Int J Cancer. 2002;98(3):456-462.
31. Crull K, Rohde M, Westphal K, et al. Biofilm formation by Salmonella enterica serovar Typhimurium colonizing solid tumours. Cell Microbiol. 2011;13(8):1223-1233.
32. Soghomonyan SA, Doubrovin M, Pike J, et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 2005;12(1):101-108.
33. Nishikawa H, Sato E, Briones G, et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 2006;116(7):1946-1954.
34. Zhu X, Zhou P, Cai J, Yang G, Liang S, Ren D. Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma. Cancer Sci. 2010;101(12):2621-2628.